Gain Therapeutics (GANX) AI Stock Analysis

• Market Cap: $69.02M
• Dividend Yield: N/A
• Average Volume (3M): 352.33K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: N/A
• EPS Growth: 49.82%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.19
• Shares Outstanding: 35,948,605
• 10 Day Avg. Volume: 502,439
• 30 Day Avg. Volume: 352,330
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.70
• Enterprise Value/Revenue: 590.95
• Enterprise Value/Gross Profit: -764.05
• Enterprise Value/Ebitda: -2.82
• 1Y Price Target: $8.00
• Price Target Upside: 330.11% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 46 Neutral
• Price Target: ―

Gain Therapeutics is currently challenged by significant financial difficulties, with no revenue growth and persistent losses impacting profitability. These weaknesses heavily weigh down the stock score. Despite these challenges, technical analysis shows mixed signals, and recent positive corporate events related to Parkinson’s treatment offer some hope for future prospects. However, the negative valuation metrics further underscore the risks, leading to an overall cautious outlook.

Positive Factors

Clinical Trials

The Phase 1b clinical study for GT-02287 in Parkinson’s disease reached its original enrollment target ahead of schedule.

Financial Support

Gain Therapeutics raised $7M from a stock and warrants offering, providing financial support into early 2026 and past key trial data releases.

Innovation and Strategy

The company's focus on innovative allosteric therapies positions it as a forward-thinking player in the biotechnology sector.

Negative Factors

Financial Performance

The company reported a wider net loss than forecasted, primarily due to higher-than-expected operating expenses.

Risks and Challenges

Risks include, but are not limited to: delays in advancing preclinical candidates into clinical studies, unexpected safety issues, and negative trial results.

Gain Therapeutics Business Overview & Revenue Model

Company Description

Gain Therapeutics, Inc. (GANX) is a biotechnology company operating in the healthcare sector, focusing on discovering and developing novel therapies to treat rare genetic disorders and neurological diseases. The company utilizes its proprietary SEE-Tx platform to identify and optimize allosteric binding sites on proteins, which can be targeted to restore normal function in misfolded proteins, a common cause of many serious diseases.

How the Company Makes Money

Gain Therapeutics primarily makes money through partnerships, collaborations, and licensing agreements with larger pharmaceutical and biotechnology companies. These partnerships usually involve upfront payments, milestone payments based on the achievement of development or regulatory milestones, and royalties on future sales of products developed using Gain's technology. Additionally, the company may receive research grants and funding for specific projects aimed at discovering therapies for rare diseases.

Gain Therapeutics Financial Statement Overview

Summary

Gain Therapeutics is facing significant financial challenges. The lack of revenue growth and persistent losses hinder profitability. While the company maintains low leverage, declining equity and asset levels raise concerns about financial stability. The negative cash flow highlights liquidity issues, impacting the company's operational sustainability.

Income Statement

Gain Therapeutics has faced declining revenues over the years, with 2024 showing no revenue. The company has persistent negative net income and EBIT, indicating profitability challenges. Gross profit margins are negative when revenue is present, showing inefficiencies in operations.

Balance Sheet

The company maintains a relatively low level of debt with a debt-to-equity ratio of 0.03 for 2024, which is a positive aspect. However, the declining stockholders' equity and total assets indicate potential risks in financial stability. The equity ratio decreased significantly over the years, suggesting increased reliance on liabilities.

Cash Flow

Gain Therapeutics struggles with negative operating cash flow, though there is improvement in free cash flow due to reduced capital expenditures. The operating cash flow to net income ratio is unfavorable, showing issues in converting profits into cash. Free cash flow remains negative, reflecting ongoing liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	82.24K	0.00	55.18K	140.11K	164.99K	28.88K
Gross Profit	-63.61K	-84.07K	-25.20K	75.94K	-7.00M	-2.23M
EBITDA	-17.21M	-19.79M	-22.17M	-17.78M	-13.82M	-3.47M
Net Income	-18.59M	-20.41M	-22.27M	-17.59M	-13.89M	-3.58M
Balance Sheet
Total Assets	9.83M	12.12M	18.61M	24.10M	38.99M	9.60M
Cash, Cash Equivalents and Short-Term Investments	6.69M	10.39M	16.79M	20.14M	36.88M	7.49M
Total Debt	229.17K	653.01K	1.03M	1.27M	1.61M	1.26M
Total Liabilities	6.14M	4.78M	6.03M	5.22M	4.17M	3.40M
Stockholders Equity	3.70M	7.34M	12.58M	18.88M	34.82M	6.20M
Cash Flow
Free Cash Flow	-9.53M	-18.90M	-18.88M	-14.81M	-12.46M	-3.26M
Operating Cash Flow	-9.53M	-18.87M	-18.87M	-14.69M	-12.37M	-3.24M
Investing Cash Flow	-43.45K	4.98M	10.22M	-14.77M	-94.21K	-20.83K
Financing Cash Flow	7.99M	13.01M	12.64M	-78.77K	41.77M	10.49M

Gain Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GANX, the sentiment is Positive. The current price of 1.86 is above the 20-day moving average (MA) of 1.65, above the 50-day MA of 1.68, and below the 200-day MA of 1.91, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 58.12 is Neutral, neither overbought nor oversold. The STOCH value of 60.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GANX.

Gain Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ICCC	54 Neutral	$56.54M	32.38	6.61%	―	21.75%	―
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
CUE	51 Neutral	$64.55M	―	-195.55%	―	-0.11%	43.47%
KRON	51 Neutral		―		―	21.15%	46.44%
PDSB	50 Neutral	$60.16M	―	-156.16%	―	―	25.26%
GANX	46 Neutral	$69.02M	―	-240.21%	―	―	49.82%
STRO	40 Neutral	$76.25M	―	-347.64%	―	-38.31%	-36.91%

Gain Therapeutics Corporate Events

Gain Therapeutics Unveils New Parkinson’s Treatment Data

On April 10, 2025, Gain Therapeutics announced the presentation of new preclinical data and the design of a Phase 1b clinical study for GT-02287, a promising treatment for Parkinson’s disease. The data, presented at the AD/PD 2025 International Conference, highlighted GT-02287’s potential to modify disease progression by reducing key biomarkers of neurodegeneration and inflammation in preclinical models. The ongoing Phase 1b study aims to assess the safety and pharmacokinetics of GT-02287 in Parkinson’s patients, with results expected to inform a Phase 2 study in late 2025. This development underscores Gain Therapeutics’ strategic positioning in the biotech industry, potentially offering a novel therapeutic approach for Parkinson’s disease and enhancing its market presence.

Spark’s Take on GANX Stock

According to Spark, TipRanks’ AI Analyst, GANX is a Underperform.

Gain Therapeutics is currently facing financial struggles, particularly in terms of revenue and cash flow, which significantly impact its stock score. Technical indicators suggest the stock is in a bearish phase, adding to the cautious outlook. However, recent corporate events, such as progress in clinical trials and leadership changes, provide some positive momentum and potential for future growth.

To see Spark’s full report on GANX stock, click here.

Gain Therapeutics Advances GT-02287 in Parkinson’s Trials

On February 6, 2025, Gain Therapeutics announced the advancement of their clinical development for GT-02287, a promising therapy for Parkinson’s disease. Following a successful Phase 1 study, they have begun a Phase 1b trial in Australia, aiming to demonstrate its disease-modifying effects. The company plans to continue its research and potentially expand trials, leveraging positive feedback from the FDA and maintaining strong financial health to support operations.